MA54595A - Procédé de préparation d'agglomérats sphériques de timapiprant - Google Patents
Procédé de préparation d'agglomérats sphériques de timapiprantInfo
- Publication number
- MA54595A MA54595A MA054595A MA54595A MA54595A MA 54595 A MA54595 A MA 54595A MA 054595 A MA054595 A MA 054595A MA 54595 A MA54595 A MA 54595A MA 54595 A MA54595 A MA 54595A
- Authority
- MA
- Morocco
- Prior art keywords
- timapiprant
- preparing spherical
- spherical agglomerates
- agglomerates
- preparing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18248081 | 2018-12-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA54595A true MA54595A (fr) | 2022-04-06 |
Family
ID=65010443
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA054596A MA54596A (fr) | 2018-12-27 | 2019-12-19 | Composition pharmaceutique comprenant des agglomérats sphériques de timapiprant |
MA054595A MA54595A (fr) | 2018-12-27 | 2019-12-19 | Procédé de préparation d'agglomérats sphériques de timapiprant |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA054596A MA54596A (fr) | 2018-12-27 | 2019-12-19 | Composition pharmaceutique comprenant des agglomérats sphériques de timapiprant |
Country Status (4)
Country | Link |
---|---|
US (2) | US20220184059A1 (fr) |
EP (2) | EP3902794A1 (fr) |
MA (2) | MA54596A (fr) |
WO (2) | WO2020136093A1 (fr) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0324763D0 (en) | 2003-10-23 | 2003-11-26 | Oxagen Ltd | Use of compounds in therapy |
GB0504150D0 (en) | 2005-03-01 | 2005-04-06 | Oxagen Ltd | Microcrystalline material |
US20130052190A1 (en) * | 2011-02-22 | 2013-02-28 | Oxagen Limited | CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions |
GB201121557D0 (en) | 2011-12-15 | 2012-01-25 | Oxagen Ltd | Process |
GB201322273D0 (en) | 2013-12-17 | 2014-01-29 | Atopix Therapeutics Ltd | Process |
US9668975B2 (en) * | 2014-10-14 | 2017-06-06 | PharmaDax Inc. | Method of preparing drug agglomerate |
-
2019
- 2019-12-19 MA MA054596A patent/MA54596A/fr unknown
- 2019-12-19 US US17/421,701 patent/US20220184059A1/en not_active Abandoned
- 2019-12-19 US US17/421,710 patent/US20220184060A1/en not_active Abandoned
- 2019-12-19 EP EP19832373.5A patent/EP3902794A1/fr active Pending
- 2019-12-19 EP EP19832673.8A patent/EP3902795A1/fr active Pending
- 2019-12-19 MA MA054595A patent/MA54595A/fr unknown
- 2019-12-19 WO PCT/EP2019/086458 patent/WO2020136093A1/fr unknown
- 2019-12-19 WO PCT/EP2019/086471 patent/WO2020136095A1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
WO2020136093A1 (fr) | 2020-07-02 |
US20220184060A1 (en) | 2022-06-16 |
EP3902795A1 (fr) | 2021-11-03 |
WO2020136095A1 (fr) | 2020-07-02 |
US20220184059A1 (en) | 2022-06-16 |
EP3902794A1 (fr) | 2021-11-03 |
MA54596A (fr) | 2022-04-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA51988A (fr) | Procédé pour la préparation de composés utiles à traiter l'amyotrophie spinale | |
MA52665A (fr) | Procédé d'amélioration de l'expression de l'hémoglobine foetale | |
MA53920A (fr) | Procédé de fourniture d'administration sous-cutanée d'anticorps anti-cd38 | |
DK3386511T3 (da) | Fremgangsmåder til behandling af huntingtons sygdom | |
MA50169A (fr) | Procédé de production d'un électrocatalyseur | |
MA45155A (fr) | Procédés de préparation d'oligomères morpholino de phosphorodiamidate | |
MA48723A (fr) | Procédé de production d'anticorps multispécifiques | |
MA44651A (fr) | Procédé de préparation d'échantillons pour analyse et procédé d'analyse | |
MA45183A (fr) | Procédés de préparation d'oligomères morpholino de phosphorodiamidate | |
MA49775A (fr) | Procédés de préparation d'oligomères morpholino de phosphorodiamidate | |
MA53370A (fr) | Procédé et intermédiaires pour la préparation de bilastine | |
MA49700A (fr) | Procédé amélioré pour la préparation de dérivés d'aminopyrimidine | |
MA55917A (fr) | Procédé de cristallisation de dérivés d'aripiprazole dans des formulations à libération prolongée pour le traitement de la schizophrénie | |
MA42423A (fr) | Procédé de préparation d'un revêtement | |
MA54396A (fr) | Procédé de préparation de n-phénylpyrazole-1-carboxamides | |
MA50647A (fr) | Procédé de régulation d'un puits | |
MA45768A (fr) | Procédé pour la préparation de compositions d'immunoglobulines | |
EP3310377A4 (fr) | Méthode de traitement de la maladie de crohn | |
MA50124A (fr) | Procédé de préparation de tubulysines et d'intermédiaires de celles-ci | |
MA46100A (fr) | Composition pharmaceutique comprenant de la rosuvastatine et de l'ézétimibe et son procédé de préparation | |
MA51432A (fr) | Procédé de préparation d'une amino-pyrimidine et de ses intermédiaires | |
FR3048968B1 (fr) | Procede de preparation d'alkylamines | |
MA50548A (fr) | Dispositifs et procédé de préparation et de réalisation de tatouages cornéens | |
FR3052767B1 (fr) | Procede de production de cristal d'apatite et cristal d'apatite | |
EP3429569A4 (fr) | Méthodes destinées à prévenir ou à traiter la maladie de parkinson par farnésylation de paris |